Electroretinographic modifications induced by agomelatine: A novel avenue to the understanding of the claimed antidepressant effect of the drug?

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 907-914

  Fornaro, Michele ^a   Bandini, Fabio ^b   Cestari, Luca ^c   Cordano, Christian ^d   Ogliastro, Carla ^d   Albano, Claudio ^d   De Berardis, Domenico ^e   Martino, Matteo ^d   Escelsior, Andrea ^d   Rocchi, Giulio ^d   Fornaro, Pantaleo ^d   De Pasquale, Concetta ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b IRCCS Istituto Giannina Gaslini   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Presidio Ospedaliero G Mazzini   (Italy)

Author keywords

Dopamine, 5 HT2C; Electroretinogram; ERG

Indexed keywords

AGOMELATINE;

ADULT; AMPLITUDE MODULATION; ANTIDEPRESSANT ACTIVITY; ARTICLE; B WAVE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; ELECTRORETINOGRAPHY; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; NORMAL HUMAN; RETINA CONE; SINGLE DRUG DOSE;

EID: 84901468535     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S63459     Document Type: Article

References (67)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. DC: American Psychiatric Association; 2013.
3. Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:102-111.
4. Perlis RH. Betting on biomarkers. Am J Psychiatry. 2011;168(3):234-236.
5. Fornaro M, Aguglia E, Dell'Osso L, Perugi G. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs? Expert Opin Pharmacother. 2011;12(18):2817-2831.
6. Lavoie J, Illiano P, Sotnikova TD, Gainetdinov RR, Beaulieu JM, Hébert M. The electroretinogram as a biomarker of central dopamine and serotonin: potential relevance to psychiatric disorders. Biol Psychiatry. 2014;75(6):479-486.
7. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006;67 Suppl 6:3-8.
8. Lavoie J, Maziade M, Hébert M. The brain through the retina: the flash electroretinogram as a tool to investigate psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:129-134.
9. Perossini M, Fornaro P. Electroretinographic effects induced in humans by psychopharmacologic agents. Doc Ophthalmol. 1990;75(1):1-6.
10. Filip V, Balik J. Possible indication of dopaminergic blockade in man by electroretinography. Int Pharmacopsychiatry. 1978;13(3):151-156.
11. Fornaro P, Castrogiovanni P, Perossini M, Placidi GF, Cavallacci G. Electroretinography (ERG) as a tool of investigation in human psychopharmacology. Electroretinographic changes induced by a combination of carbi-dopa and levo-dopa. Acta Neurol (Napoli). 1980;2(4):293-299.
12. Bubl E, Tebartz Van Elst L, Gondan M, Ebert D, Greenlee MW. Vision in depressive disorder. World J Biol Psychiatry. 2009;10(4 Pt 2):377-384.
13. Bubl E, Kern E, Ebert D, Bach M, Tebartz van Elst L. Seeing gray when feeling blue? Depression can be measured in the eye of the diseased. Biol Psychiatry. 2010;68(2):205-208.
14. Fornaro P, Castrogiovanni P, Dell'Osso L, Perossini M, Placidi G, Tassi G. Electroretinography (ERG) as a tool of investigation on dopaminergic activity in man. ERG changes induced by perphenazine and bromocriptine. Res Commun Psychol Psychiatr Behav. 1984;9:307-323.
15. Fornaro M, Bandini F, Ogliastro C, et al. Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background? J Affect Disord. 2011;135(1-3):154-159.
16. Fornaro P, Dell'Osso L, Perossini M, Placidi GF, Castrogiovanni P. Effects of nomifensine on dopaminergic transmission in healthy volunteers evaluated by means of the electroretinographic technique. Acta Neurol (Napoli). 1984;6(1):5-10.
17. Bartel P, Blom M, Robinson E, van der Meyden C, Sommers DK, Becker P. The effects of levodopa and haloperidol on flash and pattern ERGs and VEPs in normal humans. Doc Ophthalmol. 1990;76(1):55-64.
18. Porciatti V, Alesci R, Bagnoli P, Signorini G, Raffaelli A. Serotonin depletion modifies the pigeon electroretinogram. Doc Ophthalmol. 1989;72(1):93-100.
19. Lavoie MP, Lam RW, Bouchard G, et al. Evidence of a biological effect of light therapy on the retina of patients with seasonal affective disorder. Biol Psychiatry. 2009;66(3):253-258.
20. Zawilska JB. The role of dopamine in the regulation of melatonin biosynthesis in vertebrate retina. Acta Neurobiol Exp (Wars). 1994;54 Suppl:47-56.
21. Lavoie J, Rosolen SG, Chalier C, Hébert M. Negative impact of melatonin ingestion on the photopic electroretinogram of dogs. Neurosci Lett. 2013;543:78-83.
22. Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012;21(10):1503-1522.
23. Martínez-Campa C, González A, Mediavilla MD, et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer. 2009;101(9):1613-1619.
24. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8(3):287-304.
25. Sanchez Barcelo EJ, Martinez-Campa C, Mediavilla D, Gonzalez A, Alonso-Gonzalez C, Cos S. Melatonin and melatonergic drugs as therapeutic agents: ramelteon and agomelatine, the two most promising melatonin receptor agonists. Recent Pat Endocr Metab Immune Drug Discov. 2007;1:142-151.
26. Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry. 2013;203:179-187.
27. Howland RH. Publication bias and outcome reporting bias: agomelatine as a case example. J Psychosoc Nurs Ment Health Serv. 2011;49(9):11-14.
28. Opal MD, Klenotich SC, Morais M, et al. Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. Mol Psychiatry. 2013.
29. Pérez-León JA, Sarabia G, Miledi R, García-Alcocer G. Distribution of 5-hydroxytriptamine2C receptor mRNA in rat retina. Brain Res Mol Brain Res. 2004;125(1-2):140-142.
30. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954-964.
31. Milanese M, Tardito D, Musazzi L, et al. Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes. BMC Neurosci. 2013;14:75.
32. Tardito D, Milanese M, Bonifacino T, et al. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neurosci. 2010;11:68.
33. Sohn CH, Lam RW. Update on the biology of seasonal affective disorder. CNS Spectr. 2005;10(8):635-646; quiz 1-14.
34. Lam RW, Beattie CW, Buchanan A, Mador JA. Electroretinography in seasonal affective disorder. Psychiatry Res. 1992;43(1):55-63.
35. Stockton RA, Slaughter MM. b-wave of the electroretinogram. A reflection of ON bipolar cell activity. J Gen Physiol. 1989;93(1):101-122.
36. Green DG, Kapousta-Bruneau NV. A dissection of the electroretinogram from the isolated rat retina with microelectrodes and drugs. Vis Neurosci. 1999;16(4):727-741.
37. Gagné AM, Lavoie J, Lavoie MP, Sasseville A, Charron MC, Hébert M. Assessing the impact of non-dilating the eye on full-field electroretinogram and standard flash response. Doc Ophthalmol. 2010;121(3):167-175.
38. Kramer SG. Dopamine: a retinal neurotransmitter. I. Retinal uptake, storage, and light-stimulated release of H3-dopamine in vivo. Invest Ophthalmol. 1971;10(6):438-452.
39. Cohen AI, Todd RD, Harmon S, O'Malley KL. Photoreceptors of mouse retinas possess D4 receptors coupled to adenylate cyclase. Proc Natl Acad Sci U S A. 1992;89(24):12093-12097.
40. Muresan Z, Besharse JC. D2-like dopamine receptors in amphibian retina: localization with fluorescent ligands. J Comp Neurol. 1993;331(2): 149-160.
41. Biedermann B, Fröhlich E, Grosche J, Wagner HJ, Reichenbach A. Mammalian Muller (glial) cells express functional D2 dopamine receptors. Neuroreport. 1995;6(4):609-612.
42. Nguyen-Legros J, Simon A, Caillé I, Bloch B. Immunocytochemical localization of dopamine D1 receptors in the retina of mammals. Vis Neurosci. 1997;14(3):545-551.
43. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108(1):17-40.
44. Tosini G, Fukuhara C. The mammalian retina as a clock. Cell Tissue Res. 2002;309(1):119-126.
45. Zawilska JB, Nowak JZ. Dopamine D4-like receptors in vertebrate retina: does the retina offer a model for the D4-receptor analysis? Pol J Pharmacol. 1997;49(4):201-211.
46. Pozdeyev N, Tosini G, Li L, et al. Dopamine modulates diurnal and circadian rhythms of protein phosphorylation in photoreceptor cells of mouse retina. Eur J Neurosci. 2008;27(10):2691-2700.
47. Hawlina M, Jenkins HG, Ikeda H. Diurnal variations in the electroretinographic c-wave and retinal melatonin content in rats with inherited retinal dystrophy. Doc Ophthalmol. 1992;79(2):141-150.
48. Zawilska J, Nowak JZ. Regulation of melatonin biosynthesis in vertebrate retina: involvement of dopamine in the suppressive effects of light. Folia Histochem Cytobiol. 1991;29(1):3-13.
49. Jaber M, Robinson SW, Missale C, Caron MG. Dopamine receptors and brain function. Neuropharmacology. 1996;35(11):1503-1519.
50. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78(1):189-225.
51. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000;24(1):125-132.
52. De Berardis D, Marini S, Fornaro M, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci. 2013;14(6):12458-12483.
53. Fujieda H, Scher J, Hamadanizadeh SA, Wankiewicz E, Pang SF, Brown GM. Dopaminergic and GABAergic amacrine cells are direct targets of melatonin: immunocytochemical study of mt1 melatonin receptor in guinea pig retina. Vis Neurosci. 2000;17(1):63-70.
54. Scher J, Wankiewicz E, Brown GM, Fujieda H. MT(1) melatonin receptor in the human retina: expression and localization. Invest Ophthalmol Vis Sci. 2002;43(3):889-897.
55. Manglapus MK, Iuvone PM, Underwood H, Pierce ME, Barlow RB. Dopamine mediates circadian rhythms of rod-cone dominance in the Japanese quail retina. J Neurosci. 1999;19(10):4132-4141.
56. Lavoie J, Gagne AM, Lavoie MP, Sasseville A, Charron MC, Hebert M. Circadian variation in the electroretinogram and the presence of central melatonin. Doc Ophthalmol. 2010;120(3):265-272.
57. Emser W, Dechoux R, Weiland M, Wirz-Justice A. Melatonin decreases the amplitude of the b-wave of the human electroretinogram. Experientia. 1993;49(8):686-687.
58. Gagné AM, Danilenko KV, Rosolen SG, Hébert M. Impact of oral melatonin on the electroretinogram cone response. J Circadian Rhythms. 2009;7:14.
59. Solís-Chagoyán H, Mendoza-Vargas L, Fuentes-Pardo B. Melatonin modulates the ERG circadian rhythm in crayfish. Comp Biochem Physiol A Mol Integr Physiol. 2008;149(4):373-379.
60. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Sixth Revision. Helsinki: WMA (Word Medical Association); 2008.
61. Weleber RG. The effect of age on human cone and rod ganzfeld electroretinograms. Invest Ophthalmol Vis Sci. 1981;20(3):392-399.
62. Brûlé J, Lavoie MP, Casanova C, Lachapelle P, Hébert M. Evidence of a possible impact of the menstrual cycle on the reproducibility of scotopic ERGs in women. Doc Ophthalmol. 2007;114(3):125-134.
63. Schneider T, Zrenner E. Effects of D-1 and D-2 dopamine antagonists on ERG and optic nerve response of the cat. Exp Eye Res. 1991;52(4): 425-430.
64. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118(1):69-77.
65. Sharpley AL, Rawlings NB, Brain S, McTavish SF, Cowen PJ. Does agomelatine block 5-HT2C receptors in humans? Psychopharmacology (Berl). 2011;213(2-3):653-655.
66. Chenu F, Shim S, El Mansari M, Blier P. Role of melatonin, serotonin 2B, and serotonin 2C receptors in modulating the firing activity of rat dopamine neurons. J Psychopharmacol. 2014;28(2):162-167.
67. Fornaro M. Beyond monoamines towards the development of novel antidepressants. Journal of Psychopathology. 2012;18:226-233.